Nanobiotix is continuing to find fresh ways to eke money out of its Johnson & Johnson-partnered, phase 3-stage cancer drug. | ...

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

Thermo Fisher Scientific is breaking out the big bills to score a clinical research treat. With $8.875 billion in cash, the ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...

Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...

Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...

Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...

Roche’s Genentech unit is laying off staff at its Bay Area headquarters for at least the third time this year, saying goodbye ...

Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study. | ...

GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. | GSK once dreamed of ...